NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its first-quarter net loss nearly doubled year over year as the firm gears up for initial diagnostic product launches.
 
The Rehovot, Israel-based firm had no revenues for the three-month period ended March 31. The firm expects to have its initial microRNA-based diagnostic tests for cancer approved for use in CLIA labs by the end of this year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.

In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.

CNBC reports that half of academic researchers leave after about five years.

Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.